Neeraj Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Neeraj Singh has a total of 223 co-authors. Here are the top co-authors by number of shared publications:
- Krista L. Lentine
SSM Health Saint Louis University Hospital, United States
4 shared publications - Matthew Cooper
Division of Transplant Surgery, Medical College of Wisconsin, Milwaukee, WI, USA
4 shared publications - Mona D. Doshi
Department of Medicine, University of Michigan, Ann Arbor, MI
4 shared publications Todd Pesavento
Ohio State Univ ‐ Nephrology‐Internal Medicine, Columbus, Ohio, USA
4 shared publications- Kenneth J. Woodside
University of Michigan, Ann Arbor, Michigan
3 shared publications - Martha Pavlakis
Harvard Medical School, Boston, MA, USA
3 shared publications
Latest Publications
- Open Access
- 13 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (8) , 1601-1613
Recommendations to overcome barriers to transplant fellowship training: A report from the American Society of Transplantation Fellows Task Force
- 13 May 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 25 (8) , 1601-1613
Open AccessRecommendations to overcome barriers to transplant fellowship training: A report from the American Society of Transplantation Fellows Task Force
- Open Access
- 16 March 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (8) , 1473-1485
Generating strategies for a national comeback in pancreas transplantation: A Delphi survey and US conference report
- 16 March 2024
- Published by Elsevier in American Journal of Transplantation
- Vol. 24 (8) , 1473-1485
Open AccessGenerating strategies for a national comeback in pancreas transplantation: A Delphi survey and US conference report
- 30 June 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (6) , 1089-1094
Exacerbation of Racial Disparities in Living Donor Kidney Transplantation During the COVID-19 Pandemic
Complex behavioral assessment is necessary to comprehensively assess in vivo manipulations in rodent models for neuropsychiatric disorders. Operant behavioral paradigms provide rich datasets and allow for the careful analysis of behavioral phenotypes. However, one major limitation in these studies is the expense and work-load that are required using traditional methods. The equipment for commercial operant boxes can be prohibitively expensive, and the daily experimenter effort and mouse costs required for these studies is extensive. Rodents are generally trained on task-specific paradigms for months, tested every day for 5–7 d/week. Additionally, appetitive paradigms usually require food restriction and are also commonly run in the non-active light phase of the rodent circadian rhythm. These limitations make operant behavioral testing especially difficult during adolescence, a time period of interest with regards to the development of adult-like phenotypes and a high-risk period for the development of neuropsychiatric disorders, including those which involve impulsive behavior. In order to address these issues, we developed an automated, inexpensive, open-source method which allows the implementation of most standard operant paradigms in the homecage of rodents in shorter time frames without food restriction, and with much less experimenter effort. All construction and code for the do-it-yourself Nautiyal Automated Modular Instrumental Conditioning (DIY-NAMIC) system are open source. We demonstrate their utility here by measuring impulsive behavior in a pharmacology experiment, as well as in adolescent mice. Visual Abstract
- 30 June 2022
- Published by Wolters Kluwer Health in Kidney360
- Vol. 3 (6) , 1089-1094
Exacerbation of Racial Disparities in Living Donor Kidney Transplantation During the COVID-19 Pandemic
Complex behavioral assessment is necessary to comprehensively assess in vivo manipulations in rodent models for neuropsychiatric disorders. Operant behavioral paradigms provide rich datasets and allow for the careful analysis of behavioral phenotypes. However, one major limitation in these studies is the expense and work-load that are required using traditional methods. The equipment for commercial operant boxes can be prohibitively expensive, and the daily experimenter effort and mouse costs required for these studies is extensive. Rodents are generally trained on task-specific paradigms for months, tested every day for 5–7 d/week. Additionally, appetitive paradigms usually require food restriction and are also commonly run in the non-active light phase of the rodent circadian rhythm. These limitations make operant behavioral testing especially difficult during adolescence, a time period of interest with regards to the development of adult-like phenotypes and a high-risk period for the development of neuropsychiatric disorders, including those which involve impulsive behavior. In order to address these issues, we developed an automated, inexpensive, open-source method which allows the implementation of most standard operant paradigms in the homecage of rodents in shorter time frames without food restriction, and with much less experimenter effort. All construction and code for the do-it-yourself Nautiyal Automated Modular Instrumental Conditioning (DIY-NAMIC) system are open source. We demonstrate their utility here by measuring impulsive behavior in a pharmacology experiment, as well as in adolescent mice. Visual Abstract
- 6 August 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (10) , e14432
Pancreas transplantation perceptions and practice: Results from a national US survey
Background: Due to a substantial decline in pancreas transplantation (PT) across the United States over the past 15 years, we sought to understand the perceptions and practices of US PT programs.Methods: Surveys were sent to members of the American Society of Transplantation Surgeons and the American Society of Transplantation by email and professional society postings between August 2019 and November 2019.Results: One hundred twenty three responses were recorded from 56 unique programs. Program characteristics were obtained from the Scientific Registry of Transplant Recipients. Respondents were transplant surgeons (71%), transplant nephrologists (17%), trainees (9%), and allied professionals (3%). Programs were defined according to annual volume as: low (20). High‐volume programs reported that these factors were most important for increased PT: expansion of recipient selection, more aggressive donor utilization, and hiring of PT program‐specific personnel. At both the program and national level, the vast majority (82% and 79%, respectively) felt the number of PTs currently performed are not in balance with patients' needs.Conclusions: Overall, programs reported that the option of PT is not offered adequately to diabetic patients and that strategies to maintain higher PT volume are most evident at intermediate, and especially, high‐volume programs.
- 6 August 2021
- Published by Wiley in Clinical Transplantation
- Vol. 35 (10) , e14432
Pancreas transplantation perceptions and practice: Results from a national US survey
Background: Due to a substantial decline in pancreas transplantation (PT) across the United States over the past 15 years, we sought to understand the perceptions and practices of US PT programs.Methods: Surveys were sent to members of the American Society of Transplantation Surgeons and the American Society of Transplantation by email and professional society postings between August 2019 and November 2019.Results: One hundred twenty three responses were recorded from 56 unique programs. Program characteristics were obtained from the Scientific Registry of Transplant Recipients. Respondents were transplant surgeons (71%), transplant nephrologists (17%), trainees (9%), and allied professionals (3%). Programs were defined according to annual volume as: low (20). High‐volume programs reported that these factors were most important for increased PT: expansion of recipient selection, more aggressive donor utilization, and hiring of PT program‐specific personnel. At both the program and national level, the vast majority (82% and 79%, respectively) felt the number of PTs currently performed are not in balance with patients' needs.Conclusions: Overall, programs reported that the option of PT is not offered adequately to diabetic patients and that strategies to maintain higher PT volume are most evident at intermediate, and especially, high‐volume programs.
- Open Access
- 20 December 2020
- Published by Wiley in Clinical Transplantation
- Vol. 35 (2) , e14177
Approach to pancreas transplant during the COVID‐19 pandemic
- 20 December 2020
- Published by Wiley in Clinical Transplantation
- Vol. 35 (2) , e14177
Open AccessApproach to pancreas transplant during the COVID‐19 pandemic
- Open Access
- 5 October 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (4) , 1556-1563
Defining the roles and responsibilities of the kidney transplant medical director: A necessary step for future training, mentoring, and professional development
- 5 October 2020
- Published by Elsevier in American Journal of Transplantation
- Vol. 21 (4) , 1556-1563
Open AccessDefining the roles and responsibilities of the kidney transplant medical director: A necessary step for future training, mentoring, and professional development
- 15 May 2017
- Published by Wiley in Clinical Transplantation
- Vol. 31 (9)
Kidney outcomes in patients with liver cirrhosis and chronic kidney disease receiving an orthotopic liver transplant alone
Kidney transplant in patients with liver cirrhosis and nondialysis chronic kidney disease (CKD) is controversial. We report 14 liver cirrhotic patients who had persistently low MDRD‐6 estimated glomerular filtration rate (e‐GFR) 2 for ≥3 months and underwent either liver transplant alone (LTA; n=9) or simultaneous liver‐kidney transplant (SLKT; n=5). Pretransplant, patients with LTA compared with SLKT had lower serum creatinine (2.5±0.73 vs 4.6±0.52 mg/dL, P=.001), higher MDRD‐6 e‐GFR (21.0±7.2 vs 10.3±2.0 mL/min/1.73 m2, P=.002), higher 24‐hour urine creatinine clearance (34.2±8.8 vs 18.0±2.2 mL/min, P=.002), lower proteinuria (133.2±117.7 vs 663±268.2 mg/24 h, P=.0002), and relatively normal kidney biopsy and ultrasound findings. Post‐LTA, the e‐GFR (mL/min/1.73 m2) increased in all nine patients, with mean e‐GFR at 1 month (49.8±8.4), 3 months (49.6±8.7), 6 months (49.8±8.1), 12 months (47.6±9.2), 24 months (47.9±9.1), and 36 months (45.1±7.3) significantly higher compared to pre‐LTA e‐GFR (P≤.005 at all time points). One patient developed end‐stage renal disease 9 years post‐LTA and another patient expired 7 years post‐LTA. The low e‐GFR alone in the absence of other markers or risk factors of CKD should not be an absolute criterion for SLKT in patients with liver cirrhosis.
- 15 May 2017
- Published by Wiley in Clinical Transplantation
- Vol. 31 (9)
Kidney outcomes in patients with liver cirrhosis and chronic kidney disease receiving an orthotopic liver transplant alone
Kidney transplant in patients with liver cirrhosis and nondialysis chronic kidney disease (CKD) is controversial. We report 14 liver cirrhotic patients who had persistently low MDRD‐6 estimated glomerular filtration rate (e‐GFR) 2 for ≥3 months and underwent either liver transplant alone (LTA; n=9) or simultaneous liver‐kidney transplant (SLKT; n=5). Pretransplant, patients with LTA compared with SLKT had lower serum creatinine (2.5±0.73 vs 4.6±0.52 mg/dL, P=.001), higher MDRD‐6 e‐GFR (21.0±7.2 vs 10.3±2.0 mL/min/1.73 m2, P=.002), higher 24‐hour urine creatinine clearance (34.2±8.8 vs 18.0±2.2 mL/min, P=.002), lower proteinuria (133.2±117.7 vs 663±268.2 mg/24 h, P=.0002), and relatively normal kidney biopsy and ultrasound findings. Post‐LTA, the e‐GFR (mL/min/1.73 m2) increased in all nine patients, with mean e‐GFR at 1 month (49.8±8.4), 3 months (49.6±8.7), 6 months (49.8±8.1), 12 months (47.6±9.2), 24 months (47.9±9.1), and 36 months (45.1±7.3) significantly higher compared to pre‐LTA e‐GFR (P≤.005 at all time points). One patient developed end‐stage renal disease 9 years post‐LTA and another patient expired 7 years post‐LTA. The low e‐GFR alone in the absence of other markers or risk factors of CKD should not be an absolute criterion for SLKT in patients with liver cirrhosis.
- Open Access
- 30 August 2015
- Published by Elyns Group LLC in Archives of Case Reports in Clinical Medicine
- Vol. 1 (1)
Milky Serum in Hypertriglyceridemia: Clinical Image
- 30 August 2015
- Published by Elyns Group LLC in Archives of Case Reports in Clinical Medicine
- Vol. 1 (1)
Open AccessMilky Serum in Hypertriglyceridemia: Clinical Image
- Open Access
- 1 September 2014
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (9) , 2189-2191
Renal Failure in a Kidney Transplant Recipient—BK Virus Nephropathy or Rejection?
- 1 September 2014
- Published by Elsevier in American Journal of Transplantation
- Vol. 14 (9) , 2189-2191
Open AccessRenal Failure in a Kidney Transplant Recipient—BK Virus Nephropathy or Rejection?
- 24 June 2014
- Published by Wiley in Clinical Transplantation
- Vol. 28 (8) , 845-854
The risk of recurrent IgA nephropathy in a steroid‐free protocol and other modifying immunosuppression
Recurrent glomerulonephritis is an important cause of kidney allograft failure. The effect of immunosuppression on recurrent IgA nephropathy (IgAN) is unclear. We analyzed the impact of steroids and other immunosuppression on the risk of recurrent IgAN post‐kidney transplantation. Between June 1989 and November 2008, 3311 kidney transplants were performed at our center. IgAN was the primary disease in 124 patients; of these, 75 (60.5%) patients received steroid‐based immunosuppression (15 undergoing late steroid withdrawal), and 49 (39.5%) were maintained on steroid‐free immunosuppression. Recurrent IgAN was diagnosed in 27 of 124 (22%) patients in clinically indicated kidney allograft biopsies over a median follow‐up of 6.86 ± 5.4 yr. On cox proportional hazards model multivariate analysis, the hazard risk (HR) of IgAN recurrence was significantly higher in patients managed with steroid‐free (HR 8.59: 3.03, 24.38, p < 0.001) and sirolimus‐based (HR = 3.00:1.16, 7.75, p = 0.024) immunosuppression without antilymphocyte globulin induction (HR = 4.5: 1.77, 11.73, p = 0.002). Mycophenolate use was associated with a lower risk (HR = 0.42: 0.19, 0.95, p = 0.036), whereas cyclosporine did not have a significant impact on the risk of IgAN recurrence (p = 0.61). These results warrant future prospective studies regarding the role of steroids and other immunosuppression drugs in reducing recurrence of IgAN and other glomerulonephritis post‐transplant.
- 24 June 2014
- Published by Wiley in Clinical Transplantation
- Vol. 28 (8) , 845-854
The risk of recurrent IgA nephropathy in a steroid‐free protocol and other modifying immunosuppression
Recurrent glomerulonephritis is an important cause of kidney allograft failure. The effect of immunosuppression on recurrent IgA nephropathy (IgAN) is unclear. We analyzed the impact of steroids and other immunosuppression on the risk of recurrent IgAN post‐kidney transplantation. Between June 1989 and November 2008, 3311 kidney transplants were performed at our center. IgAN was the primary disease in 124 patients; of these, 75 (60.5%) patients received steroid‐based immunosuppression (15 undergoing late steroid withdrawal), and 49 (39.5%) were maintained on steroid‐free immunosuppression. Recurrent IgAN was diagnosed in 27 of 124 (22%) patients in clinically indicated kidney allograft biopsies over a median follow‐up of 6.86 ± 5.4 yr. On cox proportional hazards model multivariate analysis, the hazard risk (HR) of IgAN recurrence was significantly higher in patients managed with steroid‐free (HR 8.59: 3.03, 24.38, p < 0.001) and sirolimus‐based (HR = 3.00:1.16, 7.75, p = 0.024) immunosuppression without antilymphocyte globulin induction (HR = 4.5: 1.77, 11.73, p = 0.002). Mycophenolate use was associated with a lower risk (HR = 0.42: 0.19, 0.95, p = 0.036), whereas cyclosporine did not have a significant impact on the risk of IgAN recurrence (p = 0.61). These results warrant future prospective studies regarding the role of steroids and other immunosuppression drugs in reducing recurrence of IgAN and other glomerulonephritis post‐transplant.